A Systematic Review of the Epidemiology and Disease Burden of Congenital and Immune-Mediated Thrombotic Thrombocytopenic Purpura

被引:2
|
作者
Du, Ping [1 ]
Cristarella, Tiffany [2 ]
Goyer, Camille [2 ]
Moride, Yola [2 ,3 ]
机构
[1] Takeda Dev Ctr Amer Inc, Global Evidence & Outcomes, Cambridge, MA 02142 USA
[2] YolaRX Consultants Inc, Montreal, PQ, Canada
[3] Rutgers State Univ, Ctr Pharmacoepidemiol & Treatment Sci, New Brunswick, NJ USA
来源
JOURNAL OF BLOOD MEDICINE | 2024年 / 15卷
关键词
thrombotic thrombocytopenic purpura; epidemiology; burden of illness; disease management; patient-reported outcomes; ADAMTS13; THERAPEUTIC PLASMA-EXCHANGE; FRENCH NATIONAL REGISTRY; SEVERE ADAMTS13 DEFICIENCY; SINGLE-CENTER EXPERIENCE; CLINICAL CHARACTERISTICS; HIGH PREVALENCE; ADULT PATIENTS; OUTCOMES; TTP; MANAGEMENT;
D O I
10.2147/JBM.S464365
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Congenital (cTTP) and immune-mediated (iTTP) thrombotic thrombocytopenic purpura are serious and rare clotting disorders resulting from a deficiency in the ADAMTS13 enzyme. A systematic review was conducted using the Ovid (R) MEDLINE & Embase databases to synthesize the epidemiology and burden of cTTP and iTTP worldwide (from January 1, 2010, to February 6, 2020, with an update that covered the period January 1, 2020-February 11, 2022). Outcomes of interest were incidence and prevalence of TTP, incidence of acute episodes, mortality, burden of illness (eg complications, healthcare utilization, patient-reported outcomes) and disease management. A total of 221 eligible observational studies were included. The incidence rate of acute episodes ranged from 0.19-0.35 person-years in adult patients with cTTP, and 1.81-3.93 per million persons per year for iTTP in the general population. Triggers of acute episodes were similar for cTTP and iTTP, with pregnancy and infection the most commonly observed. Exacerbation in patients with iTTP varied widely, ranging from 2.4-63.1%. All-cause mortality was observed in 0-13.4% of patients with cTTP, across studies and follow-up periods, and in 1.1% (median follow-up: 0.4 years) to 18.8% (1 year) of patients with iTTP during acute episodes. Cardiovascular, renal, and neurological disease were common complications. TTP also led to work disturbances, feelings of anxiety and depression, and general activity impairment. TTP treatment regimens used were generally reflective of current treatment guidelines. The evidence identified describes a high patient burden, highlighting the need for effective treatment regimens leading to improvements in outcomes. Considerable evidence gaps exist, particularly for disease epidemiology, patient-reported outcomes, costs of disease management, and associated healthcare resource utilization. This review may help increase disease awareness and highlights the need for additional real-world studies, particularly in geographical regions outside the United States and Western Europe.
引用
收藏
页码:363 / 386
页数:24
相关论文
共 50 条
  • [21] Immune-mediated thrombotic thrombocytopenic purpura: don't miss the boat
    Picod, Adrien
    Zafrani, Lara
    Azoulay, Elie
    INTENSIVE CARE MEDICINE, 2024, 50 (02) : 287 - 290
  • [22] Immune-mediated thrombotic thrombocytopenic purpura: don’t miss the boat
    Adrien Picod
    Lara Zafrani
    Elie Azoulay
    Intensive Care Medicine, 2024, 50 : 287 - 290
  • [23] Immune-mediated thrombotic thrombocytopenic purpura prognosis is affected by blood pressure
    Joseph, Adrien
    Eloit, Martin
    Azoulay, Elie
    Kaplanski, Gilles
    Provot, Francois
    Presne, Claire
    Wynckel, Alain
    Grange, Steven
    Rondeau, Eric
    Pene, Frederic
    Delmas, Yahsou
    Lautrette, Alexandre
    Barbet, Christelle
    Mousson, Christiane
    Coindre, Jean-Philippe
    Perez, Pierre
    Jamme, Matthieu
    Augusto, Jean-Francois
    Poullin, Pascale
    Jacobs, Frederic
    El Karoui, Khalil
    Vigneau, Cecile
    Ulrich, Marc
    Kanouni, Tarik
    Le Quintrec, Moglie
    Hamidou, Mohamed
    Ville, Simon
    Charvet-Rumpler, Anne
    Ojeda-Uribe, Mario
    Godmer, Pascal
    Fremeaux-Bacchi, Veronique
    Veyradier, Agnes
    Halimi, Jean-Michel
    Coppo, Paul
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2022, 6 (04)
  • [24] Efficacy and safety of daratumumab in multiresistant immune-mediated thrombotic thrombocytopenic purpura
    Weisinger, Julia
    Bouzid, Raida
    Ranta, Dana
    Woaye-Hune, Pascal
    Cohen-Aubart, Fleur
    Gaible, Clotilde
    Marjanovic, Zora
    Corre, Elise
    Joly, Anne-Christine
    Baylatry, Minh-Tam
    Joly, Berangere S.
    Veyradier, Agnes
    Coppo, Paul
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (05) : 1951 - 1958
  • [25] Treatment of immune-mediated thrombotic thrombocytopenic purpura: A decisive turning point
    Poullin, P.
    TRANSFUSION CLINIQUE ET BIOLOGIQUE, 2021, 28 (04) : 380 - 385
  • [26] More on the use of frontline caplacizumab in immune-mediated thrombotic thrombocytopenic purpura
    Picod, Adrien
    Benhamou, Ygal
    Bouzid, Raida
    Veyradier, Agnes
    Coppo, Paul
    BLOOD ADVANCES, 2023, 7 (12) : 2678 - 2680
  • [27] Deleterious neurological impact of diagnostic delay in immune-mediated thrombotic thrombocytopenic purpura
    Renaud, Arthur
    Caristan, Aurelie
    Seguin, Amelie
    Agard, Christian
    Blonz, Gauthier
    Canet, Emmanuel
    Eveillard, Marion
    Godmer, Pascal
    Graveleau, Julie
    Lecouffe-Desprets, Marie
    Maisonneuve, Herve
    Perrin, Francois
    Hamidou, Mohamed
    Neel, Antoine
    PLOS ONE, 2021, 16 (11):
  • [28] Successful treatment with daratumumab for splenectomy refractory immune-mediated thrombotic thrombocytopenic purpura
    Jansen, A. J. Gerard
    Rab, Minke A. E.
    te Boekhorst, Peter A. W.
    Leebeek, Frank W. G.
    BRITISH JOURNAL OF HAEMATOLOGY, 2024,
  • [29] Efficacy and safety of azathioprine during remission of immune-mediated thrombotic thrombocytopenic purpura
    Bichard, Christian
    Mancini, Ilaria
    Agosti, Pasquale
    Capecchi, Marco
    De Leo, Pasqualina
    Arcudi, Sara
    Ferrari, Barbara
    Trisolini, Silvia Maria
    Longu, Francesco
    Fozza, Claudio
    Artoni, Andrea
    Peyvandi, Flora
    BLOOD ADVANCES, 2022, 6 (18) : 5463 - 5466
  • [30] Immune-mediated thrombotic thrombocytopenic purpura following COVID-19 vaccination
    Picod, Adrien
    Rebibou, Jean-Michel
    Dossier, Antoine
    Cador, Berengere
    Ribes, David
    Vasco-Moynet, Claire
    Stephan, Caroline
    Bellal, Mathieu
    Wynckel, Alain
    Poullin, Pascale
    Peju, Edwige
    Ricard, Laure
    Kahn, Jean-Emmanuel
    Bouzid, Raida
    Benhamou, Ygal
    Joly, Berangere
    Veyradier, Agnes
    Coppo, Paul
    BLOOD, 2022, 139 (16) : 2565 - +